ioAVATAR
Immune oncology Drug Discovery & Decision - Advanced ex Vivo Approach To Accelerate Response prediction for combined therapies in ovarian cancer
Funded projects, calls, countries and funding organisations related to this cancer type.
Immune oncology Drug Discovery & Decision - Advanced ex Vivo Approach To Accelerate Response prediction for combined therapies in ovarian cancer
Characterization of stromal and innate lymphoid cell populations involved in immunotherapy resistance in High-Grade Serous Ovarian Cancer through multiOMICS analysis
Anti-PD1 and Niraparib (PARPi) combination therapy in gynae carcinosarcoma: Identification of response-predictive biomarkers and resistance mechanisms
Biomarkers for diagnosis and prognosis of endometrial carcinoma
Proteogenomic and targeted metabolomic analysis of ovarian cancer heterogeneity and its contribution to recurrence and therapy resistance.
Clinical utility of tumour heterogeneity in triple negative breast cancer and high-grade serous ovarian carcinoma for prediction of therapy response
Immune Cells as Predictors for Early Diagnosis and Chemotherapy Toxicity in Ovarian Cancer